Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Mouhssin Oufir, PhD, Head of DMPK & Bioanalytical Sciences Department 24 octobre 2019 – 17h
RT-PCR and Western blot were not able to detect the two following ABC transporters, hMDR1 (P-gp) and hBCRP, involved in active transport in the hBMEC (human Brain microvascular endothelial cell). Whereas QTAP approach was able to detect but not quantify P-gp and BCRP in the cell membrane preparation.
The DDI (Drug-Drug interactions) guidelines (FDA and EMA) both quote these two transporter proteins as being highly relevant in ADME studies. Thus, our results reveal a major limitation for the use of the hBMEC cell line as in vitro human BBB model for the screening of drug candidates.
Key learning objectives
Introduction to Quantitative Targeted Absolute Proteomics
Application of QTAP in research
Advantages of QTAP versus Western blot or other approaches
About our speaker Mouhssin Oufir
Dr. Mouhssin Oufir holds a MSc in protein engineering (1999) and a PhD in Biochemistry (2004). He was a bioanalytical responsible in CRP-Gabriel Lippmann in Luxembourg from 2004-2008. In 2008, Dr. Oufir joined SGS Life Science Services in Belgium as a GLP study director. He spent 9 years as bioanalytical and DMPK head within the Pharmazentrum in Switzerland before joining in May 2019 Oncodesign as Head of DMPK and Bioanalytical Sciences Department.
18 rue Jean Mazen - FR - 21000 Dijon Tel.+33 380 788 260